Pre-surgical oncolytic virotherapy improves breast cancer outcomes.
Oncoimmunology
; 8(11): e1655363, 2019.
Article
en En
| MEDLINE
| ID: mdl-31646102
ABSTRACT
Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, controls metastases and sensitizes tumors to immune checkpoint inhibitors (ICIs).
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2019
Tipo del documento:
Article